Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Cyteir Therapeutics
763E Concord Avenue
Cambridge, MA 02138
Phone: 857-285-4140
http://cyteir.com

Cyteir Therapeutics is a leader in the discovery and development of novel therapeutics based on the biology of DNA repair and synthetic lethality for the treatment of cancer and autoimmune diseases. The company's initial approach takes advantage of the "gain-of-function" from DNA damage overload to induce selective self-destruction of cells by targeting disease-induced RAD51 transport. Cyteir's lead molecules were initially discovered using the company's drug discovery platform, which enables identification of primary cells with tunable genetic constraints.

Key Contact
Name
Kevin Mills, Ph.D.
Title
Co-Founder
Funding Events

Date
Amount
Type
Investors
03/08/18 $29,000,000 Series B Celgene Corporation
DROIA Oncology Ventures
Lightstone Ventures
Venrock
10/15/19 $40,200,000 Series B Celgene Corporation
DROIA Oncology Ventures
Lightstone Ventures
Novo Holdings
Osage University Partners
Venrock
02/11/21 $80,000,000 Series C Acuta Capital Partners
Ally Bridge Group
Ample Plus Fund
Avidity Partners
CaaS Capital Management
DROIA Oncology Ventures
Janus Henderson Investors
Lightstone Ventures
Novo Holdings
Osage University Partners
RA Capital Management
Venrock


Featured Reading